CRISPR Therapeutics CRSP
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 53rd percentile, 5-year average -8.1x
Around its usual level · 59th percentile, 5-year average 2.4x
#3463 of 5331 stocks by PB (1 = cheapest)
Above its usual level · 69th percentile, 5-year average 347.6x
#4990 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.49 | – | 2.41 | 59% (pricier than usual) | #3463 of 5331 (1 = cheapest) |
| PE | -8.93 | -9.79 | -8.05 | 53% (pricier than usual) | – |
| PS | 162.77 | 82.24 | 347.55 | 69% (pricier than usual) | #4990 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CRSP.
Sign in to join the discussion.